These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 15827279)

  • 21. Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model.
    Teva A; Porrozzi R; Oliveira-Neto MP; Grimaldi GJ
    J Parasitol; 2005 Aug; 91(4):976-8. PubMed ID: 17089782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitivity to Glucantime of Leishmania viannia isolated from patients prior to treatment.
    Robledo SM; Valencia AZ; Saravia NG
    J Parasitol; 1999 Apr; 85(2):360-6. PubMed ID: 10219320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of localized cutaneous leishmaniasis].
    Buffet P; Caumes E; Gentilini M
    Ann Dermatol Venereol; 1994; 121(6-7):503-11. PubMed ID: 7702288
    [No Abstract]   [Full Text] [Related]  

  • 24. Antimony in plasma and skin of patients with cutaneous leishmaniasis--relationship with side effects after treatment with meglumine antimoniate.
    Neves DB; Caldas ED; Sampaio RN
    Trop Med Int Health; 2009 Dec; 14(12):1515-22. PubMed ID: 19954451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
    Shazad B; Abbaszadeh B; Khamesipour A
    Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
    Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA; Jaffary F; Moradi S; Derakhshan R; Haftbaradaran E
    BMC Complement Altern Med; 2007 Apr; 7():13. PubMed ID: 17466071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
    Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG
    J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis.
    Arevalo I; Tulliano G; Quispe A; Spaeth G; Matlashewski G; Llanos-Cuentas A; Pollack H
    Clin Infect Dis; 2007 Jun; 44(12):1549-54. PubMed ID: 17516397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z; Nakhli A; Rassaii S
    Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract]   [Full Text] [Related]  

  • 31. Refractory cutaneous leishmaniasis in an adolescent: initial manifestation of type 1 diabetes.
    Atabek ME; Pirgon O; Unal E
    J Infect; 2006 Oct; 53(4):290-1. PubMed ID: 16466661
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study.
    Esfandiarpour I; Dabiri SH
    Int J Dermatol; 2007 Aug; 46(8):848-52. PubMed ID: 17651170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.
    Firooz A; Khamesipour A; Ghoorchi MH; Nassiri-Kashani M; Eskandari SE; Khatami A; Hooshmand B; Gorouhi F; Rashighi-Firoozabadi M; Dowlati Y
    Arch Dermatol; 2006 Dec; 142(12):1575-9. PubMed ID: 17178983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran.
    Mohammadzadeh M; Behnaz F; Golshan Z
    J Infect Public Health; 2013 Apr; 6(2):120-4. PubMed ID: 23537825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
    Salmanpour R; Handjani F; Nouhpisheh MK
    J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial.
    Velez I; Agudelo S; Hendrickx E; Puerta J; Grogl M; Modabber F; Berman J
    Ann Intern Med; 1997 Feb; 126(3):232-6. PubMed ID: 9027276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucantime fever with parenteral meglumine antimonate in patients of cutaneous leishmaniasis.
    Rashid BN; Tabassum S; Ullah Rao MS; Masood S; Abbas MM; Mumtaz MJ
    J Coll Physicians Surg Pak; 2010 Jul; 20(7):496. PubMed ID: 20642959
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol.
    Momeni AZ; Aminjavaheri M
    Eur J Dermatol; 2003; 13(1):40-3. PubMed ID: 12609780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.
    Mlika RB; Hamida MB; Hammami H; Jannet SB; Badri T; Fenniche S; Mokhtar I
    Dermatol Ther; 2012; 25(6):615-8. PubMed ID: 23210761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of meglumine antimoniate in canine leishmaniasis.
    Lamothe J
    Vet Rec; 2004 Mar; 154(12):378. PubMed ID: 15074332
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.